Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients

Summary

This study will evaluate the safety and tolerability of the cfor the first time in mild to moderate COPD patients.

Timeline

Start

2007-10-04

Primary completion

2008-12-15

Completion

2008-12-15

Publications

• Watz H, Mistry SJ, Lazaar AL; IPC101939 investigators. Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD. Pulm Pharmacol Ther. 2013 Oct;26(5):588-95. doi: 10.1016/j.pupt.2013.05.004. Epub 2013 May 21.

Drugs

Indications